Race Oncology (ASX: RAC) — Perfil da empresa, notícias e dados financeiros
Race Oncology Limited (ASX:RAC) is an ASX-listed clinical stage biopharmaceutical company developing bisantrene, a novel anthracycline
Race Oncology
Race Oncology is a clinical-stage biopharmaceutical company focused on addressing unmet medical needs in cancer care and cardiovascular protection. The company develops targeted small molecule therapeutics designed to act both as potent inhibitors of fat mass and obesity-associated RNA demethylase enzymes and as cardioprotective oncological agents. Its clinical and preclinical research programs target hematological cancers, including acute myeloid leukemia, as well as solid tumors such as breast cancer and melanoma. Through reformulation and combination treatment strategies, the company aims to reduce chemotherapy-induced cardiac damage while delivering improved therapeutic outcomes across oncology indications.
Resumo
Operações
Produtos e/ou serviços de Race Oncology
- Targeted Oncology Therapeutics: Development of small molecule chemotherapeutic agents targeting m6A RNA demethylase enzymes, specifically fat mass and obesity-associated proteins, to disrupt cancer cell survival mechanisms in relapsed or refractory hematological malignancies and advanced solid tumors.
- Cardioprotective Chemotherapy Formulations: Research and formulation of novel intravenous drug candidates designed to prevent anthracycline-induced cardiotoxicity in cancer patients receiving standard chemotherapy regimens, enabling safer delivery of potent antineoplastic treatments without sacrificing oncological efficacy.
- Acute Myeloid Leukemia Programs: Clinical trial programs evaluating targeted small molecule monotherapies and combination regimens for adult and pediatric patients diagnosed with relapsed or refractory acute myeloid leukemia and extramedullary hematological malignancies.
- Solid Tumor Combination Therapies: Preclinical and early-phase clinical evaluation of targeted oncological molecules combined with standard chemotherapeutics, immunotherapy agents, and targeted inhibitors across solid tumor indications including triple-negative breast cancer and metastatic melanoma.
- Proprietary Pharmaceutical Reformulation: Development of optimized drug delivery systems, oral dosage forms, and improved parenteral formulations aimed at enhancing bioavailability, reducing administration complexity, and expanding intellectual property protection across global healthcare markets.
- Strategic Research Collaborations: Collaborative research partnerships with international academic institutions, oncology clinical networks, and contract development and manufacturing organizations to advance translational oncology studies, biomarker discovery, and international clinical trial execution.
equipe executiva do Race Oncology
- Peter Michael SmithExecutive Chairman
- Daniel TillettCEO, MD & Director
- Brendan BrownChief Financial Officer
- Sophia MoscovisVice President of Operations & Strategy
- Jose L. IglesiasChief Medical Officer
- Peter Gordon WebseCompany Secretary
Comunicados recentes
O que a Race Oncology (RAC) comunicou ao mercado, do mais recente para o mais antigo.
- HARNESS-1 First Cohort ClearedFato relevante
- Racura Presents CPACS Data at GCOS 2026
- Date of AGM & Closing Date for Director Nominations
- Racura Oncology Investor Briefings Perth & Auckland
- Racura raised $34.3m to Advance Three Oncology TrialsFato relevante
- Cleansing Notice
- Application for quotation of securities - RAC
Principais indicadores financeiros
Resultados divulgados pela Race Oncology, em AUD.
- Cap. de mercado
- 303,9 mi
- Receita (TTM)
- 2,8 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.1
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| — | -12,4 mi | -11,1 mi | |
| 6 mi | -3,8 mi | -4,8 mi | |
| 4 mi | -17,8 mi | -13,8 mi | |
| 3,1 mi | -13 mi | -9,9 mi |